Dysregulation of PTEN in Cardiopulmonary Vascular Remodeling Induced by Pulmonary Hypertension

Cell Biochemistry and Biophysics

Volumn 67, Issue 2, 2013, Pages 363-372

  Ravi, Yazhini ^a   Selvendiran, Karuppaiyah ^a   Meduru, Sarath ^a   Citro, Lucas ^a   Naidu, Shan ^a   Khan, Mahmood ^a   Rivera, Brian K ^a   Sai Sudhakar, Chittoor B ^a   Kuppusamy, Periannan ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Hypoxia; Monocrotaline; Proteasomal degradation; PTEN; Pulmonary hypertension

Indexed keywords

RATTUS;

CELL CYCLE PROTEIN; MONOCROTALINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME;

ANIMAL; ANOXIA; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HEART; HEART MUSCLE; HUMAN; LUNG; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER;

ANIMALS; ANOXIA; CELL CYCLE PROTEINS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HEART; HUMANS; HYPERTENSION, PULMONARY; LUNG; MONOCROTALINE; MYOCARDIUM; MYOCYTES, SMOOTH MUSCLE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; PTEN PHOSPHOHYDROLASE; RATS;

EID: 84886594011     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-011-9332-z     Document Type: Article

References (45)

1. Rabinovitch, M. (2005). Cellular and molecular pathobiology of pulmonary hypertension conference summary. Chest, 128, 642S-646S.
2. Agarwal, R., & Gomberg-Maitland, M. (2011). Current therapeutics and practical management strategies for pulmonary arterial hypertension. American Heart Journal, 162, 201-213.
3. Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., et al. (2010). Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation, 121, e46-e215.
4. Sehgal, P. B., & Mukhopadhyay, S. (2007). Pulmonary arterial hypertension: A disease of tethers, SNAREs and SNAPs? American Journal of Physiology-Heart and Circulation Physiology, 293, H77-H85.
5. Huang, J., & Kontos, C. D. (2002). Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 745-751.
6. Nemenoff, R. A., Simpson, P. A., Furgeson, S. B., Kaplan-Albuquerque, N., Crossno, J., Garl, P. J., et al. (2008). Targeted deletion of PTEN in smooth muscle cells results in vascular remodeling and recruitment of progenitor cells through induction of stromal cell-derived factor-1alpha. Circulation Research, 102, 1036-1045.
7. Nisbet, R. E., Bland, J. M., Kleinhenz, D. J., Mitchell, P. O., Walp, E. R., Sutliff, R. L., et al. (2010). Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. American Journal of Respiratory Cell and Molecular Biology, 42, 482-490.
8. Gu, J., Tamura, M., & Yamada, K. M. (1998). Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. Journal of Cell Biology, 143, 1375-1383.
9. Moon, S. K., Kim, H. M., & Kim, C. H. (2004). PTEN induces G1 cell cycle arrest and inhibits MMP-9 expression via the regulation of NF-kappaB and AP-1 in vascular smooth muscle cells. Archives of Biochemistry and Biophysics, 421, 267-276.
10. Tamguney, T., & Stokoe, D. (2007). New insights into PTEN. Journal of Cell Science, 120, 4071-4079.
11. van de Sande, T., De Schrijver, E., Heyns, W., Verhoeven, G., & Swinnen, J. V. (2002). Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Research, 62, 642-646.
12. Oudit, G. Y., & Penninger, J. M. (2009). Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovascular Research, 82, 250-260.
13. Oudit, G. Y., Sun, H., Kerfant, B. G., Crackower, M. A., Penninger, J. M., & Backx, P. H. (2004). The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. Journal of Molecular and Cellular Cardiology, 37, 449-471.
14. Noureddine, H., Gary-Bobo, G., Alifano, M., Marcos, E., Saker, M., Vienney, N., et al. (2011). Pulmonary artery smooth muscle cell senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung disease. Circulation Research, 109, 543-553.
15. Huang, J., & Kontos, C. D. (2002). PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. Journal of Biological Chemistry, 277, 10760-10766.
16. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., et al. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91, 231-241.
17. Voelkel, N. F., & Tuder, R. M. (2000). Hypoxia-induced pulmonary vascular remodeling: A model for what human disease? Journal of Clinical Investigation, 106, 733-738.
18. Moens, A. L., Takimoto, E., Tocchetti, C. G., Chakir, K., Bedja, D., Cormaci, G., et al. (2008). Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: Efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation, 117, 2626-2636.
19. Feng, N., Hoover, D. B., & Paolocci, N. (2007). Forever young? Nerve growth factor, sympathetic fibers, and right ventricle pressure overload. Circulation Research, 100, 1670-1672.
20. Itoh, T., Nagaya, N., Fujii, T., Iwase, T., Nakanishi, N., Hamada, K., et al. (2004). A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. American Journal of Respiratory and Critical Care Medicine, 169, 34-38.
21. Selvendiran, K., Kuppusamy, M. L., Bratasz, A., Tong, L., Rivera, B. K., Rink, C., et al. (2009). Inhibition of vascular smooth-muscle cell proliferation and arterial restenosis by HO-3867, a novel synthetic curcuminoid, through up-regulation of PTEN expression. Journal of Pharmacology and Experimental Therapeutics, 329, 959-966.
22. Selvendiran, K., Tong, L., Vishwanath, S., Bratasz, A., Trigg, N. J., Kutala, V. K., et al. (2007). EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. Journal of Biological Chemistry, 282, 28609-28618.
23. Ashcroft, M., Ludwig, R. L., Woods, D. B., Copeland, T. D., Weber, H. O., MacRae, E. J., et al. (2002). Phosphorylation of HDM2 by Akt. Oncogene, 21, 1955-1962.
24. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., et al. (1998). Regulation of cell death protease caspase-9 by phosphorylation. Science, 282, 1318-1321.
25. Mayo, L. D., & Donner, D. B. (2001). A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proceedings of the National Academy of Sciences of the United States of America, 98, 11598-11603.
26. Mizuno, S., Bogaard, H. J., Voelkel, N. F., Umeda, Y., Kadowaki, M., Ameshima, S., et al. (2009). Hypoxia regulates human lung fibroblast proliferation via p53-dependent and -independent pathways. Respiration Research, 10, 17.
27. Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., & Donner, D. B. (1999). NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature, 401, 82-85.
28. Robbins, I. M. (2004). Advancing therapy for pulmonary arterial hypertension: Can animal models help? American Journal of Respiratory and Critical Care Medicine, 169, 5-6.
29. Mizuno, S., Bogaard, H. J., Kraskauskas, D., Alhussaini, A., Gomez-Arroyo, J., Voelkel, N. F., et al. (2011). p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. American Journal of Physiology Lung Cellular and Molecular Physiology, 300, L753-L761.
30. Penumathsa, S. V., & Maulik, N. (2009). Resveratrol: A promising agent in promoting cardioprotection against coronary heart disease. Canadian Journal of Physiology and Pharmacology, 87, 275-286.
31. Chung, J. H., Ostrowski, M. C., Romigh, T., Minaguchi, T., Waite, K. A., & Eng, C. (2006). The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation. Human Molecular Genetics, 15, 2553-2559.
32. Weng, L. P., Brown, J. L., & Eng, C. (2001). PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Human Molecular Genetics, 10, 599-604.
33. Chen, L., Zhang, J., Gan, T. X., Chen-Izu, Y., Hasday, J. D., Karmazyn, M., et al. (2008). Left ventricular dysfunction and associated cellular injury in rats exposed to chronic intermittent hypoxia. Journal of Applied Physiology, 104, 218-223.
34. Kimura, H., Kasahara, Y., Kurosu, K., Sugito, K., Takiguchi, Y., Terai, M., et al. (1998). Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Laboratory Investigation, 78, 571-581.
35. Hershko, A. (1997). Roles of ubiquitin-mediated proteolysis in cell cycle control. Current Opinion in Cell Biology, 9, 788-799.
36. Heath, D. (1992). The rat is a poor animal model for the study of human pulmonary hypertension. Cardioscience, 3, 1-6.
37. Tamura, M., Gu, J., Danen, E. H., Takino, T., Miyamoto, S., & Yamada, K. M. (1999). PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. Journal of Biological Chemistry, 274, 20693-20703.
38. Huang, J., Niu, X. L., Pippen, A. M., Annex, B. H., & Kontos, C. D. (2005). Adenovirus-mediated intraarterial delivery of PTEN inhibits neointimal hyperplasia. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 354-358.
39. Osman, N., Ballinger, M. L., Dadlani, H. M., Getachew, R., Burch, M. L., & Little, P. J. (2008). p38 MAP kinase mediated proteoglycan synthesis as a target for the prevention of atherosclerosis. Cardiovasc Hematol Disord Drug Targets, 8, 287-292.
40. Vidavalur, R., Swarnakar, S., Thirunavukkarasu, M., Samuel, S. M., & Maulik, N. (2008). Ex vivo and in vivo approaches to study mechanisms of cardioprotection targeting ischemia/reperfusion (i/r) injury: Useful techniques for cardiovascular drug discovery. Current Drug Discovery Technologies, 5, 269-278.
41. Libby, P., Ridker, P. M., & Maseri, A. (2002). Inflammation and atherosclerosis. Circulation, 105, 1135-1143.
42. Rodriguez, O. C., Lai, E. W., Vissapragada, S., Cromelin, C., Avetian, M., Salinas, P., et al. (2009). A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1. American Journal of Pathology, 174, 2051-2060.
43. Basu, P., Sen, U., Tyagi, N., & Tyagi, S. C. (2010). Blood flow interplays with elastin: collagen and MMP: TIMP ratios to maintain healthy vascular structure and function. Journal of Vascular Health and Risk Management, 6, 215-228.
44. Perez, J., Torres, R. A., Rocic, P., Cismowski, M. J., Weber, D. S., Darley-Usmar, V. M., et al. (2011). PYK2 signaling is required for PDGF-dependent vascular smooth muscle cell proliferation. American Journal of Physiology-Cell Physiology, 301, C242-C251.
45. McKinsey, T. A., & Kass, D. A. (2007). Small-molecule therapies for cardiac hypertrophy: Moving beneath the cell surface. Nature Reviews Drug Discovery, 6, 617-635.